| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Starr Christopher M serves as a Director at MNPR. Across recent SEC filings that breaks down to 0 buys and 1 sell. Those positions are worth an estimated $2.6M at current prices.
The biggest single holding is MNPR (~$2.6M) as Director. The recent filings there lean toward selling, a net 16,800 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 14, 2025 | MNPR Monopar Therapeutics | Director | Sell | 16,800 | $40.00 | $672,020.16 | -76.5% | +133.4% | +128.2% |